Business
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
Expanding commercialization of first-line fertility treatment in the OB/GYN office to increase patient accessATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the commercial launch of FemaSeed Complete, a comprehensive fertility solution that enables OB/GYNs to perform first-line insemination entirely wi
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2GAPMaOqvqggyHfSDG8ZUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MQ--/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"Expanding commercialization of first-line fertility treatment in the OB/GYN office to increase patient access","length":109,"tagName":"p"},{"type":"text","content":"ATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the commercial launch of FemaSeed Complete, a comprehensive fertility solution that enables OB/GYNs to perform first-line insemination entirely within their own practices.","length":416,"tagName":"p"},{"type":"text","content":"An estimated 10 million women in the United States experience infertility, yet fewer than half access care, and only a very small percentage ultimately undergo IVF. At the same time, U.S. fertility rates declined again in 2025 to a record low, underscoring the growing need for earlier intervention and expanded access to care. While more than 40,000 OB/GYNs are accessible to patients, infertility specialists—fewer than 2,000 nationwide—are typically accessed by referral and concentrated in a declining number of centers, limiting access to treatment. By enabling first-line treatment in the OB/GYN office, FemaSeed Complete is positioned to expand access to care and substantially increase the addressable market.","length":717,"tagName":"p"},{"type":"text","content":"“Current fertility care delivery is not aligned with where patients seek care, creating a significant opportunity for change,” said Kathy Lee-Sepsick, CEO and Founder of Femasys. “Our market research shows strong patient interest in accessing fertility care earlier and more cost-effectively within the OB/GYN setting. Through our Femasys fertility portfolio, we are enabling physicians to perform in-office procedures that can expand care, accelerate ...